Hain Celestial Group ( HAIN) price target was raised at Citigroup to $42 from $34. Accelerating sales, EPS beat and solid outlook, Citigroup said. Maintain Buy rating . Hain Celestial numbers were increased at UBS through 2012. Company is seeing better sales, and acquisitions are boosting growth, UBS said. Neutral rating and new $34 price target. Impax Laboratories ( IPXL) numbers were raised at Goldman Sachs. Shares now seen reaching $29, and estimates were also boosted, to match the company's new guidance, Goldman said. Neutral rating. Las Vegas Sands ( LVS) price target was lowered at Credit Suisse to $55 from $56. Meaningful upside potential as its properties continue to ramp, Credit Suisse said. Maintain Outperform rating. Las Vegas Sands estimates were lowered through 2012 at Morgan Stanley. Singapore is not growing as quickly as expected, Morgan Stanley said. Overweight rating and $50 price target. Mastercard ( MA) estimates, target raised at Goldman Sachs. Shares now seen reaching $315. Estimates also increased, as higher volumes are driving margin growth, according to Goldman. Buy rating. McKesson ( MCK) price target was increased to $89 from $85 at Citigroup. Fourth-quarter EPS was inline, and revenue was better than expected, Citigroup said. Maintain Hold rating. Marathon Oil ( MRO) numbers were boosted at UBS. Shares are now seen reaching $60. Estimates were also increased, given better downstream earnings, UBS said. Buy rating. Genetics ( MYGN) numbers were increased at Goldman Sachs through 2013. Company boosted its guidance, though pricing remains uncertain, Goldman said. Sell rating and new $19 price target. MetroPCS ( PCS) estimates, target increased at Goldman Sachs through 2013. Company is leveraged to smartphone momentum, Goldman said. Neutral rating and new $18 price target. Pfizer ( PFE)estimates, target were boosted at Goldman Sachs. Shares now seen reaching $24. Estimates also raised, given expectations for increased buyback activity. Buy rating. Perrigo ( PRGO) estimates, target upped at UBS. Estimates were boosted through 2012. Generic fundamentals remain strong, UBS said. Buy rating and new $100 price target. Parexel ( PRXL) estimates, target were cut at Goldman Sachs. Shares now seen reaching $22. Estimates also lowered, to match the company's new guidance, Goldman said. Neutral rating. Molson Coors ( TAP) numbers were reduced at Goldman Sachs. Shares now seen reaching $52. Estimates also cut, given lower volume and margins, according to Goldman Sachs. Neutral rating.